Summary The effects of steroid hormones are pleiotropic. Similarly, non-steroidal oestrogen receptor antagonists such as tamoxifen exert partial agonistic effects with a species-and tissue-specific pattern. Conversely, little is known of the biological effects of non-steroidal anti-androgens, whose role has been investigated in the palliative treatment of prostate cancer. We studied the effects of the non-steroidal anti-androgen nilutamide on parameters of red blood cells, an androgen-dependent cell compartment, in 24 men with prostate cancer and compared the results with those obtained in 38 historical control patients treated with D-tryptophan-6-LHRH. Administration of the anti-androgen induced a limited rise in testosterone concentrations (from 14.1 ± 1.8 up to a maximum of 19.6 ± 2.3 nmol l-l) and a significant increase with time in haemoglobin and haematocrit (y = 12.6 g dl-I + 0.15 months and y = 37.3% + 0.46 months respectively, P = 0.008 for both), while no change occurred in red blood cell count (y = 4.19 x 106 mm-3 + 0.02 months, P = 0.2). Conversely, no variation in erythroid parameters was observed in the patients treated with the LHRH analogue (haemoglobin = 12.7 + 0.02 months, P = 0.59; haematocrit = 38.1 + 0.02 months, P = 0.9; red blood cells = 4.34 x 106 mm-3 + 0.15 months, P = 0.4). The difference between the linear regression slopes of haemoglobin in the two treatment groups was significant (F-ratio = 3.39, P = 0.03). While the stimulation of erythropoiesis induced by the anti-androgen might be due to incomplete neutralisation of endogenous androgens at the bone marrow level, a cell-specific agonistic effect of the drug cannot be excluded, thus calling into question the designation of pure antagonists which has been attributed to this class of compounds. Ongoing randomised trials should address this issue.
Orchiectomy or LHRH agonists represent the standard endocrine treatment of advanced prostatic cancer. An important drawback in palliative management of sexually active patients, however, is the loss of libido and sexual potency which accompanies testosterone (T) suppression. In recent studies, it has been shown that the administration of pure non-steroidal androgen receptor (AR) antagonists is able to interfere with the androgen negative feedback, resulting in a paradoxical state of hypergonadotropic hypergonadism (Gooren et al., 1987) , which allowed the preservation of libido and sexual potency in some patients (Sogani et al., 1984; Decensi et al., 1991; Tyrrel, 1992) . For this reason, the use of non-steroidal anti-androgens as single agents has been sought as a potential improvement in the palliative management of prostate cancer. Moreover, their broader use has been proposed in the management of androgen-related nononcological conditions (Marcondes et al., 1992) and even in the chemoprevention of prostate cancer (Crawford et al., 1992) .
At present, however, little is known not only of the clinical anti-tumour activity but also of the spectrum of biological effects resulting from administration of this class of compounds as single agents. A better understanding of this issue may be important, particularly when taking into account the heterogeneity that characterises the effects both of steroids and steroid antagonists at target level (Green, 1990; Gronemeyer, 1992; Landers & Spelsberg, 1992) . The nonsteroidal anti-oestrogen tamoxifen is the prototype of this pleiotropism, also having significant agonistic properties which are species, tissue, cell and response specific (Nayfield et al., 1991) .
The role of androgens in the physiological regulation of erythropoiesis is well established (Fried & Morley, 1985) . Within the normal range of haemoglobin (Hb), stimulation of erythropoiesis by androgens is not mediated by significant changes in erythropoietin levels (Weber et al., 1991) but is directly exerted by a nuclear AR (Claustres & Sultan, 1988 (Friedman ANOVA) respectively. The differences between the slopes of the regression lines generated by haematological data of the two treatment groups were analysed using ANOVA of regression coefficients.
Results
Before treatment there were no differences in red blood cell parameters and platelet levels between the two treatment groups (Hb, 12.6 ± 0.3 vs 12.7 ± 0.3 g dl-', P = 0.8; Hct, 37.3 1.1 vs 38.1 ± 0.9%, P = 0.5; RBC, 4.19 ± 0.1 vs 4.34±0.1 x 106mm-3, P=0.2; Plt, 236± 16.2 vs 262± 14.3 x 103 mm-3, P = 0.1; anti-androgen and LHRH agonist group respectively).
The effects of the treatments on the values of Hb, Hct and RBC are shown in Figure 1 . There was a significant increase with time in both Hb (y = 12.6 + 0.15 months, P = 0.008) and Hct (y = 37.3 + 0.46 months, P =0.008) during antiandrogen administration, while RBC remained unchanged (y = 4.19 x 106 + 0.02 months, P = 0.2). No significant variation in Plt occurred (y = 236 x 103 + 3.94 months, P = 0.3).
A plot of the change in Hb for individual patients after 3 months of anti-androgen is shown in Figure 2 . The data indicate a general increase in Hb values affecting the patient population as a whole, with a mean Hb of 0.8 ± 0.2 g dl-' (P = 0.004). In the LHRH agonist group, no variation in red blood cell parameters was noted (Figure 1 ): Hb (y = 12.7 + 0.02 months, P = 0.59), Hct (y = 38.1 + 0.02 months, P = 0.9), RBC (y = 4.34 x 106 + 0.15 months, P= 0.4). Nor was there any significant variation in Plt values (y= 262 x I03 -1.2 months, P = 0.58).
The difference in regression coefficients between the two treatment groups (indicating a different slope of the lines) was statistically significant for Hb (F-ratio = 3.39, P = 0.03), while no such difference was evident for Hct (F-ratio = 2.32, P = 0.1), RBC (F-ratio = 0.7, P = 0.47) and Plt (Fratio = 0.8, P = 0.45).
Testosterone concentrations initially and after 3, 6 and 9 months were 14. (Schwall et al., 1989) . Although the increase in red blood cell parameters observed in the patients treated with the anti-androgen may partly be the result of the anti-tumour effect on bone marrow or of a non-specific improvement in general condition, the lack of an increase in Plt levels and, more importantly, the absence of any stimulatory effect in similar patients treated with the LHRH agonist seem to argue against this as the single mechanism. The occurrence of inadequate neutralisation of increased androgens by the antagonist should also be considered, even though' the increase in T concentrations was limited and the results of pilot clinical trials seem to suggest a benefit in terms of anti-tumour activity similar to conventional androgen-suppressive manipulations (Decensi et al., 1991; Benson, 1992; Tyrrel, 1992) . This issue is currently the subject of randomised trials.
Although our observation could only be biased by the lack of a randomised comparison, the concept of a potential agonistic activity of nilutamide on erythroid parameters may also be advanced. This would imply a differential control of anti-androgen action in different target systems. Indeed, the regulation of steroid hormone action is known to be complex (Green, 1990; Gronemeyer, 1992; Landers & Spelsberg, 1992) and steroid receptor antagonists exhibit biological effects that are species, tissue, cell and response specific (Nayfield et al., 1991) . Recently, molecular biology studies have clearly shown that the pleiotropic effect of the non-steroidal antioestrogen tamoxifen is due to the selective activation of the expression of target genes that depends on cell type and promoter context, presumably through the interaction of the ligand-receptor complex with different transcriptional factors (Berry et al., 1990; Green, 1990) . Conversely, the mechanisms of action and the pharmacology of non-steroidal anti-androgens have been studied to a lesser extent. Indeed, their characterisation as pure antagonists comes almost exclusively from rodent studies using the ventral prostate as target tissue (Poyet et al., 1985; Moguilewsky et al., 1986; Furr et al., 1987) . In keeping with the above, the definition of pure antagonists is further challenged by the observation that these compounds can induce de novo nuclear AR synthesis (Steinsapir et al., 1991) and a sustained decline in prostatespecific antigen levels after their discontinuation (Kelly & Scher, 1993) . The anti-tumour efficacy of nilutamide at a lower dose (300mg daily for 1 month followed by 150mg thereafter) was recently evaluated in combination with orchiectomy in a randomised double-blind trial (Janknegt et al., 1993) . Among the reported adverse effects, anaemia was observed in 4% of nilutamide-treated patients compared with 7% of placebo patients. Although this difference was not statistically significant (X2 = 1.33, P = 0.24), a trend in favour of a stimulatory effect on erythropoiesis cannot be excluded if a continuous variable (i.e. the rise in Hb levels) were used as an end point.
Whatever the mechanisms involved may be, randomised trials currently in progress and mechanistic studies will further elucidate our phenomenological observation and the possible differences among various anti-androgens. The potential role of growth factors such as activin also remains to be established. In fact, in addition to the trophic effect on erythropoiesis (Schwall et al., 1989) , this member of the transforming growth factor P family stimulates the secretion of FSH (Schwall et al., 1989) , another effect shared with nilutamide administration (Decensi et dl., 1993) .
In clinical terms, the trophic effect on erythropoiesis is beneficial and does not necessarily raise questions on the anti-tumour activity of this class of compounds in prostate cancer, which still remains to be confirmed in comparative controlled trials. They may well find a useful role in the palliative management of selected patients in whom maintenance of sexual activity is important.
